

Alexander Nast

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8858354/publications.pdf>

Version: 2024-02-01

218
papers

12,086
citations

38660

50
h-index

30848

102
g-index

262
all docs

262
docs citations

262
times ranked

8394
citing authors

#	ARTICLE	IF	CITATIONS
1	The EAACI/GA ² LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1393-1414.	2.7	1,008
2	The EAACI/GA ² LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 868-887.	2.7	912
3	Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of Dermatological Research, 2011, 303, 1-10.	1.1	690
4	European S3 Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1-70.	1.3	683
5	The international EAACI/GA ² LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 734-766.	2.7	392
6	The international WAO/EAACI guideline for the management of hereditary angioedema – The 2017 revision and update. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1575-1596.	2.7	365
7	European S3 Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2277-2294.	1.3	353
8	European Evidence-based (S3) Guidelines for the Treatment of Acne. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1-29.	1.3	317
9	WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organization Journal, 2012, 5, 182-199.	1.6	264
10	The natural history of actinic keratosis: a systematic review. British Journal of Dermatology, 2013, 169, 502-518.	1.4	262
11	European evidence-based (S3) guideline for the treatment of acne – update 2016 – short version. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1261-1268.	1.3	247
12	S3 Guidelines on the treatment of psoriasis vulgaris (English version). Update. JDDG - Journal of the German Society of Dermatology, 2012, 10, S1-95.	0.4	235
13	Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis – International League of Dermatological Societies in cooperation with the European Dermatology Forum – Short version. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2069-2079.	1.3	234
14	Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 11-22.	1.3	191
15	The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1961-1990.	2.7	153
16	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2461-2498.	1.3	149
17	Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. British Journal of Dermatology, 2014, 170, 274-303.	1.4	141
18	The Diagnosis and Treatment of Oral Cavity Cancer. Deutsches Ärztblatt International, 2012, 109, 829-35.	0.6	140

#	ARTICLE	IF	CITATIONS
19	European consensus-based (S2k) Guideline on the Management of Herpes Zoster "guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 20-29.	1.3	125
20	A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 438-453.	1.3	122
21	German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Archives of Dermatological Research, 2007, 299, 111-138.	1.1	116
22	Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis. Journal of Investigative Dermatology, 2015, 135, 2641-2648.	0.3	116
23	European S3-Guideline on the systemic treatment of psoriasis vulgaris " Update Apremilast and Secukinumab " <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1951-1963.	1.3	116
24	S3 Guideline for the treatment of psoriasis vulgaris, update " Short version part 1 " Systemic treatment. JDDG - Journal of the German Society of Dermatology, 2018, 16, 645-669.	0.4	107
25	Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. JDDG - Journal of the German Society of Dermatology, 2007, 5, 1-119.	0.4	104
26	German S3-guidelines on the treatment of psoriasis vulgaris (short version). Archives of Dermatological Research, 2012, 304, 87-113.	1.1	96
27	Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review. Cancer Treatment Reviews, 2017, 60, 44-52.	3.4	90
28	S1 guidelines on the diagnosis and treatment of scabies " short version. JDDG - Journal of the German Society of Dermatology, 2016, 14, 1155-1167.	0.4	88
29	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris " Part 2: specific clinical and comorbid situations. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 281-317.	1.3	84
30	S3 guidelines: Epicutaneous patch testing with contact allergens and drugs " Short version, Part 1. JDDG - Journal of the German Society of Dermatology, 2019, 17, 1076-1093.	0.4	81
31	Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection " A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis. PLoS ONE, 2018, 13, e0208107.	1.1	79
32	European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1403-1414.	1.3	79
33	S2k guidelines for the treatment of pemphigus vulgaris/foiaceus and bullous pemphigoid. JDDG - Journal of the German Society of Dermatology, 2015, 13, 833-844.	0.4	76
34	Methods report on the development of the 2013 revision and update of the <scp>EAACI</scp>/²/<scp>GA</sup>2</sup>/<scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> guideline for the definition, classification, diagnosis, and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, e1-29.	2.7	75
35	Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 758-764.	1.3	74
36	Executive summary of the methods report for "The EAACI/GA²/LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update"™. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1145-1146.	2.7	74

#	ARTICLE	IF	CITATIONS
37	S2k guideline for the diagnosis of pemphigus vulgaris/foiaceus and bullous pemphigoid. JDDG - Journal of the German Society of Dermatology, 2015, 13, 713-727.	0.4	69
38	S3 - Guidelines on the treatment of psoriasis vulgaris Update 2011. JDDG - Journal of the German Society of Dermatology, 2011, 9, S1-S95.	0.4	66
39	Chronic inducible urticaria: A systematic review of treatment options. Journal of Allergy and Clinical Immunology, 2018, 141, 1726-1734.	1.5	66
40	Ivermectin and permethrin for treating scabies. The Cochrane Library, 2018, 2018, CD012994.	1.5	66
41	S2k Leitlinie Neurodermitis [atopisches Ekzem; atopische Dermatitis] â€“ Kurzversion. JDDG - Journal of the German Society of Dermatology, 2016, 14, 92-106.	0.4	65
42	European consensus-based (S2k) Guideline on the Management of Herpes Zoster â€“ guided by the European Dermatology Forum (<scp>EDF</scp>) in cooperation with the European Academy of Dermatology and Venereology (<scp>EADV</scp>), Part 1: Diagnosis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 9-19.	1.3	62
43	S2k guideline on diagnosis and treatment of atopic dermatitis â€” short version. Allergo Journal International, 2016, 25, 82-95.	0.9	60
44	Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1331-1344.	1.3	58
45	Which Antipsoriatic Drug Has the Fastest Onset of Action?â€”Systematic Review on the Rapidity of the Onset of Action. Journal of Investigative Dermatology, 2013, 133, 1963-1970.	0.3	57
46	S2k Leitlinie zur Diagnostik und Therapie des chronischen Pruritus â€“ Update â€“ Kurzversion. JDDG - Journal of the German Society of Dermatology, 2017, 15, 860-873.	0.4	56
47	Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Journal of the American Academy of Dermatology, 2019, 80, 128-138.e2.	0.6	56
48	S2k Leitlinie zur Diagnostik des Pemphigus vulgaris/foiaceus und des bullösen Pemphigoids. JDDG - Journal of the German Society of Dermatology, 2015, 13, 713-727.	0.4	54
49	German S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids). JDDG - Journal of the German Society of Dermatology, 2012, 10, 747-760.	0.4	52
50	Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis. JDDG - Journal of the German Society of Dermatology, 2015, 13, 674-689.	0.4	50
51	S2k guideline on diagnosis and treatment of atopic dermatitis â€“ short version. JDDG - Journal of the German Society of Dermatology, 2016, 14, 92-105.	0.4	49
52	Barriers to the prescription of systemic therapies for moderate-to-severe psoriasisâ€”a multinational cross-sectional study. Archives of Dermatological Research, 2013, 305, 899-907.	1.1	48
53	Efficacy and Durability of Two Hyaluronic Acid-Based Fillers in the Correction of Nasolabial Folds: Results of a Prospective, Randomized, Double-Blind, Actively Controlled Clinical Pilot Study. Dermatologic Surgery, 2011, 37, 768-775.	0.4	47
54	Methods Report: European S3 Guidelines on the systemic treatment of psoriasis vulgaris â€“ update 2015 â€“ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. Journal of the European Academy of Dermatology and Venereology, 2015, 29, e1-22.	1.3	46

#	ARTICLE	IF	CITATIONS
55	The 2016 International League of Dermatological Societies' revised glossary for the description of cutaneous lesions. <i>British Journal of Dermatology</i> , 2016, 174, 1351-1358.	1.4	46
56	The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. <i>World Allergy Organization Journal</i> , 2018, 11, 5.	1.6	45
57	Strategies for improving the quality of care in psoriasis with the use of treatment goals – a report on an implementation meeting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1-13.	1.3	44
58	Recommendations for detection of individual risk for comorbidities in patients with psoriasis. <i>Archives of Dermatological Research</i> , 2013, 305, 91-98.	1.1	44
59	S3 Guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 2. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 1187-1207.	0.4	44
60	The Treatment of Scabies. <i>Deutsches Ärzteblatt International</i> , 2016, 113, 757-762.	0.6	43
61	Guidelines on dermatomyositis – excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 321-338.	0.4	43
62	Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. <i>British Journal of Dermatology</i> , 2018, 178, 1064-1071.	1.4	43
63	Systematic review of combination therapies for mycosis fungoides. <i>Cancer Treatment Reviews</i> , 2014, 40, 927-933.	3.4	41
64	S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 55-78.	0.4	41
65	Deutsche S2k Leitlinie zur Therapie pathologischer Narben (hypertrophe Narben und Keloide). <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 747-762.	0.4	39
66	Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 1337-1342.	1.3	38
67	The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. <i>World Allergy Organization Journal</i> , 2022, 15, 100627.	1.6	37
68	Safety and Efficacy of the Tumor Necrosis Factor Antagonists. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 35-47.	1.6	36
69	A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: –AGREE-ing™ on a common base for European evidence-based psoriasis treatment guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 782-787.	1.3	34
70	Online lectures for students in dermatology: A replacement for traditional teaching or a valuable addition?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1039-1043.	1.3	34
71	On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1458-1467.	1.3	33
72	Methods and Results Report – Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis – International League of Dermatological Societies in cooperation with the European Dermatology Forum. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, e1-66.	1.3	32

#	ARTICLE	IF	CITATIONS
73	S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 2 - Special patient populations and treatment situations. JDDG - Journal of the German Society of Dermatology, 2018, 16, 806-813.	0.4	32
74	Do guidelines change the way we treat? Studying prescription behaviour among private practitioners before and after the publication of the German Psoriasis Guidelines. Archives of Dermatological Research, 2009, 301, 553-559.	1.1	30
75	German S3â€“Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm â€“ Part 1: Treatment goals and treatment recommendations. JDDG - Journal of the German Society of Dermatology, 2021, 19, 934-150.	0.4	30
76	Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis. Sexually Transmitted Infections, 2017, 93, 155-161.	0.8	29
77	Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative. British Journal of Dermatology, 2018, 178, e279-e285.	1.4	29
78	Laser treatments in early wound healing improve scar appearance: a randomized split-wound trial with nonablative fractional laser exposures vs. untreated controls. British Journal of Dermatology, 2018, 179, 1307-1314.	1.4	28
79	Topical treatments for scalp psoriasis. The Cochrane Library, 2016, 2016, CD009687.	1.5	27
80	A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis. American Journal of Clinical Dermatology, 2019, 20, 593-604.	3.3	26
81	Anogenital warts and other HPV-associated anogenital lesions in the HIV-positive patient: a systematic review and meta-analysis of the efficacy and safety of interventions assessed in controlled clinical trials. Sexually Transmitted Infections, 2017, 93, 543-550.	0.8	25
82	S2kâ€“Leitlinie: HPVâ€“assozierte LÃsionen der ÃuÃyeren Genitalregion und des Anus â€“ Genitalwarzen und Krebsvorstufen der Vulva, des Penis und der periâ€“und intraanalen Haut (Kurzfassung). JDDG - Journal of the German Society of Dermatology, 2018, 16, 242-256.	0.4	25
83	Study of Perceptions of the Extent to Which Guideline Recommendations Are Binding. Deutsches Ärztblatt International, 2013, 110, 663-8.	0.6	25
84	Translating psoriasis treatment guidelines into clinical practice â€“ the need for educational interventions and strategies for broad dissemination. Journal of Evaluation in Clinical Practice, 2008, 14, 803-806.	0.9	24
85	Diagnosis and treatment of <i>Staphylococcus aureus</i> infections of the skin and mucous membranes. JDDG - Journal of the German Society of Dermatology, 2011, 9, 953-967.	0.4	24
86	S3 guidelines for the management of anticoagulation in cutaneous surgery. JDDG - Journal of the German Society of Dermatology, 2015, 13, 346-356.	0.4	24
87	S3â€“Leitlinie zur Therapie der Psoriasis vulgaris Update â€“ Kurzfassung Teil 1 â€“ Systemische Therapie. JDDG - Journal of the German Society of Dermatology, 2018, 16, 645-670.	0.4	24
88	S2k guidelines for the treatment of psoriasis in children and adolescents â€“ Short version part 2. JDDG - Journal of the German Society of Dermatology, 2019, 17, 959-973.	0.4	24
89	A patientâ€“centred approach to biological treatment decision making for psoriasis: an expert consensus. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2390-2398.	1.3	23
90	S2k Guidelines for the diagnosis and treatment of chronic pruritus â€“ update â€“ short version. JDDG - Journal of the German Society of Dermatology, 2017, 15, 860-872.	0.4	23

#	ARTICLE	IF	CITATIONS
91	S2k - Guideline on the Therapy of Acne. JDDG - Journal of the German Society of Dermatology, 2010, 8, s1-s55.	0.4	22
92	Risk of complications due to anticoagulation during dermatosurgical procedures: a systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1603-1609.	1.3	22
93	Knowledge and use of HIV pre-exposure prophylaxis among men who have sex with men in Berlin - A multicentre, cross-sectional survey. PLoS ONE, 2018, 13, e0204067.	1.1	22
94	Topical treatments for scalp psoriasis: summary of a Cochrane Systematic Review. British Journal of Dermatology, 2017, 176, 604-614.	1.4	21
95	Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1249-1260.	1.3	21
96	Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017. British Journal of Dermatology, 2019, 180, 31-42.	1.4	21
97	S2k guidelines for the treatment of pemphigus vulgaris/foiaceus and bullous pemphigoid: 2019 update. JDDG - Journal of the German Society of Dermatology, 2020, 18, 516-526.	0.4	20
98	German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 2: Treatment monitoring and specific clinical or comorbid situations. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1092-1115.	0.4	20
99	FrÃ¼herkennung der KomorbiditÃt bei Psoriasis: Konsensusempfehlungen der Nationalen Konferenz zur Versorgung der Psoriasis. JDDG - Journal of the German Society of Dermatology, 2015, 13, 674-690.	0.4	19
100	S2k guideline: HPV-associated lesions of the external genital region and the anus - anogenital warts and precancerous lesions of the vulva, the penis, and the peri- and intra-anal skin (short version). JDDG - Journal of the German Society of Dermatology, 2018, 16, 242-255.	0.4	19
101	Evaluation of Ivermectin vs Permethrin for Treating Scabies - Summary of a Cochrane Review. JAMA Dermatology, 2019, 155, 730.	2.0	19
102	The quality of European dermatological guidelines: critical appraisal of the quality of EDF guidelines using the AGREE II instrument. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 395-403.	1.3	18
103	S2k guidelines for the use of topical preparations on the skin. JDDG - Journal of the German Society of Dermatology, 2018, 16, 376-392.	0.4	18
104	S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 1. JDDG - Journal of the German Society of Dermatology, 2019, 17, 856-870.	0.4	18
105	Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 2: Therapiemonitoring, besondere klinische Situationen und KomorbiditÃt. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1092-1117.	0.4	18
106	E-learning in the dermatological education at the CharitÃ©: evaluation of the last three years. JDDG - Journal of the German Society of Dermatology, 2008, 6, 467-472.	0.4	17
107	S1-Leitlinie zur Diagnostik und Therapie der Skabies - Kurzfassung. JDDG - Journal of the German Society of Dermatology, 2016, 14, 1160-1171.	0.4	17
108	Systematic review on the rapidity of the onset of action of topical treatments in the therapy of mild-to-moderate acne vulgaris. British Journal of Dermatology, 2014, 170, 557-564.	1.4	16

#	ARTICLE	IF	CITATIONS
109	S1 guideline diagnosis and therapy of cutaneous larva migrans (creeping disease). JDDG - Journal of the German Society of Dermatology, 2014, 12, 86-91.	0.4	16
110	Methods report on the development of the European evidence-based (S3) guideline for the treatment of acne – update 2016. Journal of the European Academy of Dermatology and Venereology, 2016, 30, e1-e28.	1.3	16
111	Rifampicin alone may be enough: is it time to abandon the classic oral clindamycin-rifampicin combination for hidradenitis suppurativa?. British Journal of Dermatology, 2019, 180, 949-950.	1.4	15
112	Evidence-based (S3) guideline for the treatment of psoriasis vulgaris – Update: –Therapeutic options– and –Efalizumab–. JDDG - Journal of the German Society of Dermatology, 2010, 8, 65-66.	0.4	14
113	Methods report on the development of the European S3 guidelines for the treatment of acne. Journal of the European Academy of Dermatology and Venereology, 2012, 26, e1-41.	1.3	14
114	S2k guideline* –Diagnosis and therapy of syphilis– short version. JDDG - Journal of the German Society of Dermatology, 2015, 13, 472-480.	0.4	14
115	Comparison of guidelines for the management of patients with high-risk and advanced cutaneous squamous cell carcinoma – a systematic review. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 25-32.	1.3	14
116	Head-to-head studies of botulinum toxin A in aesthetic medicine: Which evidence is good enough?. Journal of the American Academy of Dermatology, 2007, 56, 1066-1067.	0.6	13
117	Umgang mit Antikoagulation bei dermatochirurgischen Eingriffen in Deutschland - Ergebnisse einer Querschnittsstudie. JDDG - Journal of the German Society of Dermatology, 2013, 11, 52-59.	0.4	13
118	S1-Leitlinie zur Diagnostik und Therapie der kutanen Larva migrans (Creeping disease). JDDG - Journal of the German Society of Dermatology, 2014, 12, 86-91.	0.4	13
119	The impact of adverse reactions to injectable filler substances on quality of life: results from the Berlin Injectable Filler Safety (<scp>IFS</scp>) – study. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1013-1020.	1.3	13
120	Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 329-337.	1.3	13
121	Biosimilars: a systematic review of published and ongoing clinical trials of antipsoriatics in chronic inflammatory diseases. JDDG - Journal of the German Society of Dermatology, 2015, 13, 294-300.	0.4	12
122	S2k-Leitlinie zum Gebrauch von Präparationen zur lokalen Anwendung auf der Haut (Topika). JDDG - Journal of the German Society of Dermatology, 2018, 16, 376-392.	0.4	12
123	Therapeutic patient education and self-management support for patients with psoriasis – a systematic review. JDDG - Journal of the German Society of Dermatology, 2019, 17, 685-695.	0.4	12
124	Isotretinoin Laboratory Monitoring in Acne Treatment. JAMA Dermatology, 2022, 158, 942.	2.0	12
125	Management of anticoagulation during dermatosurgical procedures in Germany – results from a cross-sectional study. JDDG - Journal of the German Society of Dermatology, 2013, 11, 52-59.	0.4	11
126	Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?. Journal of Dermatological Treatment, 2015, 26, 520-527.	1.1	11

#	ARTICLE	IF	CITATIONS
127	Birth Outcomes in Children Fathered by Men Treated with Immunosuppressant Drugs before Conceptionâ€”A Danish Population-Based Cohort Study. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1790-1792.	0.3	11
128	Management of antithrombotic agents in dermatologic surgery before and after publication of the corresponding German evidence-based guideline. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 297-305.	0.4	11
129	Biosimilars: Ein systematischer Review zu publizierten und laufenden klinischen Studien zu Antipsoriatika bei chronisch inflammatorischen Erkrankungen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 294-301.	0.4	10
130	How Much Do We Know about Maintaining Treatment Response after Successful Acne Therapy? Systematic Review on the Efficacy and Safety of Acne Maintenance Therapy. <i>Dermatology</i> , 2016, 232, 371-380.	0.9	10
131	Adjuvant treatment of anogenital warts with systemic interferon: a systematic review and meta-analysis. <i>Sexually Transmitted Infections</i> , 2018, 94, 21-29.	0.8	10
132	Handaugmentation mit stabilisierter Hyaluronsäure (Macrolaneâ„, VRF20 und RestylaneÂ® Vital.) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	0.4	9
133	Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting. <i>Archives of Dermatological Research</i> , 2016, 308, 249-261.	1.1	9
134	A critical eye on registry data in psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 245-246.	1.4	9
135	Online consensus conferences for clinical guidelines development - a survey among participants from the International Guidelines for the Treatment of Actinic Keratosis. <i>Journal of Evaluation in Clinical Practice</i> , 2014, 20, 853-856.	0.9	8
136	Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals. <i>Rheumatology International</i> , 2019, 39, 605-618.	1.5	8
137	German evidence and consensusâ€based (S3) guideline: Vaccination recommendations for the prevention of HPVâ€associated lesions. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 479-494.	0.4	8
138	S2k guideline: Diagnosis and management of cutaneous lupus erythematosus â€“ Part 1: Classification, diagnosis, prevention, activity scores. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1236-1247.	0.4	8
139	Self-applied topical interventions for melasma: a systematic review and meta-analysis of data from randomized, investigator-blinded clinical trials. <i>British Journal of Dermatology</i> , 2022, 187, 309-317.	1.4	8
140	Drei Jahre Deutsche S3â€Leitlinie zur Therapie der Psoriasis vulgaris â€“ Hat der Aufwand sich gelohnt?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 1044-1047.	0.4	7
141	National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines. <i>Archives of Dermatological Research</i> , 2013, 305, 637-643.	1.1	7
142	S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids) â€“ Update 2020. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 312-327.	0.4	7
143	Systematic review on the maintenance of response during systemic antipsoriatic therapy. <i>British Journal of Dermatology</i> , 2015, 173, 910-921.	1.4	6
144	Off-label prescriptions and decisions on reimbursement requests in Germany - a retrospective analysis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1103-1109.	0.4	6

#	ARTICLE	IF	CITATIONS
145	Methods report: European S3â€“Guideline on the systemic treatment of psoriasis vulgaris â€“ Update Apremilast and Secukinumab â€“ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1964-1977.	1.3	6
146	Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials. British Journal of Dermatology, 2018, 178, 400-405.	1.4	6
147	State of the art treatment for stage I to III anal squamous cell carcinoma: A systematic review and meta-analysis. Radiotherapy and Oncology, 2021, 157, 188-196.	0.3	6
148	A distinctive bullous skin reaction associated with enfortumab vedotinâ€“ejfv treatment for metastatic urothelial cancer: A case report. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1781-1783.	0.4	6
149	S2kâ€“Guideline for Teledermatology. JDDG - Journal of the German Society of Dermatology, 2021, , .	0.4	6
150	Intracellular calcium responses to cholinergic stimulation of lymphocytes from healthy donors and patients with rheumatoid arthritis. Rheumatology International, 2009, 29, 497-502.	1.5	5
151	Hand augmentation with stabilized hyaluronic acid (Macrolaneâ„¢ VRF20 and Restylane^{Â®}) Tj ETQq1 1 0.784314 rgBT /Ov 8, 41-44.	0.4	5
152	Evaluation of and Perspectives on Guidelines: What Is Important?. Journal of Investigative Dermatology, 2010, 130, 2348-2349.	0.3	5
153	Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology, 2013, 68, 1040-1041.	0.6	5
154	S3â€“Leitlinie zum Umgang mit Antikoagulation bei Operationen an der Haut. JDDG - Journal of the German Society of Dermatology, 2015, 13, 346-357.	0.4	5
155	Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis. JAMA Dermatology, 2019, 155, 1380.	2.0	5
156	Prioritizing topics in guideline development: results of a twoâ€“phase online survey of dermatologist members of the <scp>EADV</scp>. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 227-233.	1.3	5
157	HIV Pre-Exposure Prophylaxis (PrEP) Counseling in Germany: Knowledge, Attitudes and Practice in Non-governmental and in Public HIV and STI Testing and Counseling Centers. Frontiers in Public Health, 2020, 8, 298.	1.3	5
158	Risk of complications due to antithrombotic agents in cutaneous surgery: a systematic review and metaâ€“analysis. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1421-1432.	0.4	5
159	S2k-Leitlinie Neurodermitis (atopisches Ekzem, atopische Dermatitis) â€“ Kurzversion. Allergo Journal, 2016, 25, 36-51.	0.1	4
160	S3-Leitlinie zur Therapie der Psoriasis vulgaris Update - Kurzfassung Teil 2 - Besondere Patientengruppen und spezielle Behandlungssituationen. JDDG - Journal of the German Society of Dermatology, 2018, 16, 806-814.	0.4	4
161	â€“Surprisingly little evidenceâ€“™ on how best to treat actinic keratosis in organ transplant recipients. British Journal of Dermatology, 2019, 180, 11-12.	1.4	4
162	Granulomatous reaction following microneedling of striae distensae. JDDG - Journal of the German Society of Dermatology, 2019, 17, 443-445.	0.4	4

#	ARTICLE	IF	CITATIONS
163	Incidences of different cancer types in dermatomyositis, polymyositis and dermatopolymyositis: results of a registry analysis. <i>British Journal of Dermatology</i> , 2020, 183, 186-188.	1.4	4
164	S3 guideline: Management of anticoagulants and antiplatelet agents in cutaneous surgery. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1531-1546.	0.4	4
165	Three years after the publication of the German (S3) evidence based Psoriasis Guidelines "Was it worth the effort?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 1044-1047.	0.4	3
166	S3-Leitlinie zur Therapie der Psoriasis vulgaris - Update: "Übersicht der Therapieoptionen" und "Efalizumab". <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 8, 65-66.	0.4	3
167	Maintenance therapy: acne as a chronic disease. <i>British Journal of Dermatology</i> , 2011, 164, 1181-1182.	1.4	3
168	Disclosure of potential conflicts of interest in dermatological guidelines in Germany "an analysis" status quo and quo vadis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 297-304.	0.4	3
169	S2k-Leitlinie zur Therapie des Pemphigus vulgaris/foiaceus und des bullösen Pemphigoid. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 833-845.	0.4	3
170	Off-Label-Use und Entscheidungen über Anträge auf Kostenübernahme in Deutschland - eine retrospektive Analyse. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1103-1110.	0.4	3
171	The value and pitfalls of biologics registries for psoriasis. <i>British Journal of Dermatology</i> , 2018, 178, 301-302.	1.4	3
172	Methodenreport der S3-Leitlinie zur Durchführung des Epikutantests mit Kontaktallergenen und Arzneimitteln. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, .	0.4	3
173	Sustained improvement of surgical scar appearance 1 year after early intervention with nonablative fractional laser treatment: a randomized controlled split-wound trial. <i>British Journal of Dermatology</i> , 2020, 183, 1138-1140.	1.4	3
174	Measuring importance of outcomes to patients: a cross-sectional survey for the German anal cancer guideline. <i>Journal of Clinical Epidemiology</i> , 2021, 129, 40-50.	2.4	3
175	S2k guideline: Diagnosis and management of cutaneous lupus erythematosus "Part 2: Therapy, risk factors and other special topics. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1371-1395.	0.4	3
176	Perioperative management of antithrombotic drugs in skin surgery "A survey of dermatologists in Germany. <i>JDDG - Journal of the German Society of Dermatology</i> , 0, , .	0.4	3
177	Offenlegung potenzieller Interessenkonflikte in dermatologischen Leitlinien in Deutschland - eine Analyse - Status Quo und Quo Vadis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 297-304.	0.4	2
178	Acne treatment in the field: how guidelines and other sources can be included in daily practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 2-5.	1.3	2
179	Methodological standards in medical reporting. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 107-120.	0.4	2
180	Methodische Standards in der medizinischen Berichterstattung. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 107-122.	0.4	2

#	ARTICLE	IF	CITATIONS
181	Vaccination against HPV-Associated Neoplasias. Geburtshilfe Und Frauenheilkunde, 2014, 74, 233-241.	0.8	2
182	S2k-Leitlinie* â€žDiagnostik und Therapie der Syphilisâ€œ â€œ Kurzfassung S2k guideline* â€œDiagnosis and therapy of syphilisâ€œ” â€œshort version. JDDG - Journal of the German Society of Dermatology, 2015, 13, 472-481.	0.4	2
183	Antibiotic resistance in acne. Lancet Infectious Diseases, The, 2016, 16, 775-776.	4.6	2
184	Which treatment options do acne patients prefer?. JDDG - Journal of the German Society of Dermatology, 2017, 15, 77-81.	0.4	2
185	Welche BehandlungsmÃ¶glichkeiten bevorzugen Akne-Patienten?. JDDG - Journal of the German Society of Dermatology, 2017, 15, 77-81.	0.4	2
186	Umgang mit Antithrombotika bei Operationen an der Haut vor und nach Publikation der entsprechenden S3-Leitlinie. JDDG - Journal of the German Society of Dermatology, 2018, 16, 297-306.	0.4	2
187	Methods Report: Update of the German S3 Guideline for the Treatment of Psoriasis vulgaris. JDDG - Journal of the German Society of Dermatology, 2018, 16, .	0.4	2
188	Treatment of extensive, recalcitrant keloids using a combination of intralesional cryosurgery, triamcinolone, 5-â€œfluorouracil and hyaluronidase. JDDG - Journal of the German Society of Dermatology, 2019, 17, 735-737.	0.4	2
189	S2k-Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematodes â€œ Teil 2: Therapie, Risikofaktoren und spezielle Fragestellungen. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1371-1395.	0.4	2
190	An open label prospective randomized trial to compare the efficacy of coal tar-salicylic acid ointment versus calcipotriol/betamethasone dipropionate ointment in the treatment of limited chronic plaque psoriasis. Indian Journal of Dermatology, 2015, 60, 198.	0.1	2
191	Methods used for indirect comparisons of systemic treatments for psoriasis. A systematic review. Skin Health and Disease, 0, , .	0.7	2
192	Impact of off-label use regulations on patient care in dermatology â€œ a prospective study of cost coverage applications filed by tertiary dermatology clinics throughout Germany. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 2241-2249.	1.3	2
193	The Value of Indirect Comparisons of Systemic Biologics for Psoriasis: Interpretation of Efficacy Findings. Dermatology and Therapy, 2022, 12, 1711-1727.	1.4	2
194	Can physician's self-estimates be used as a valid instrument to determine prescription frequencies of anti-psoriatic drugs? Comparison of the results of a cross-sectional study using self-estimates with actual prescription behavior documented in a cohort study. Pharmacoepidemiology and Drug Safety, 2013, 22, 1154-1158.	0.9	1
195	P092â€œ...Does The Addition Of Symbols Make Guidelines Recommendations Clearer? Results From An Online Survey. BMJ Quality and Safety, 2013, 22, 52.3-53.	1.8	1
196	Hypopigmentierte Maculae bei einem jungen Mann. JDDG - Journal of the German Society of Dermatology, 2014, 12, 272-274.	0.4	1
197	Treating actinic keratosis. British Journal of Dermatology, 2016, 174, 260-261.	1.4	1
198	Paternal drug exposure: plenty of confounders, few conclusions. British Journal of Dermatology, 2017, 176, 847-848.	1.4	1

#	ARTICLE	IF	CITATIONS
199	Introducing the new Evidence-Based Dermatology section. British Journal of Dermatology, 2017, 177, 885-887.	1.4	1
200	Efficacy of topical caffeine in male androgenetic alopecia. JDDG - Journal of the German Society of Dermatology, 2017, 15, 734-741.	0.4	1
201	Hidden treasures: exploring selective publication of trials and trial outcomes in biological treatment for plaque psoriasis. British Journal of Dermatology, 2019, 181, 601-602.	1.4	1
202	Impact of pharmaceutical industry involvement in the external review of clinical practice guidelines – A case study. Journal of Evaluation in Clinical Practice, 2020, 26, 718-727.	0.9	1
203	HIV Pre-exposure Prophylaxis (PrEP): Knowledge, attitudes and counseling practices among physicians in Germany – A cross-sectional survey. PLoS ONE, 2021, 16, e0250895.	1.1	1
204	Reporting in the clinical trials evaluating scabies treatments. Annals of Parasitology, 2016, 62, 153-5.	0.1	1
205	Factors that motivate men who have sex with men in Berlin, Germany, to use or consider using HIV pre-exposure prophylaxis – A multi-methods analysis of data from a multicentre survey. PLoS ONE, 2021, 16, e0260168.	1.1	1
206	E-Learning in der dermatologischen Lehre an der CharitÄ©: Evaluation der vergangenen drei Jahre. JDDG - Journal of the German Society of Dermatology, 2008, 6, ---.	0.4	0
207	Reply to Alberto Giannetti, MD, PhD commentary regarding the European S3 – Guidelines on the systemic treatment of Psoriasis. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 368-369.	1.3	0
208	Hypopigmented macules in a young man. JDDG - Journal of the German Society of Dermatology, 2014, 12, 272-274.	0.4	0
209	Wytyczne EAACI/GA2LEN/EDF/WAO dotyczÄ...ce definicji, klasyfikacji, rozpoznawania i leczenia pokrzywki: weryfikacja z 2013 roku z poprawkami. Alergologia Polska - Polish Journal of Allergology, 2015, 2, T1-T23.	0.0	0
210	Leitlinie Dermatomyositis – Auszug aus der interdisziplinÄren S2 – Leitlinie zu Myositissyndromen der deutschen Gesellschaft fÄ¼r Neurologie. JDDG - Journal of the German Society of Dermatology, 2016, 14, e1.	0.4	0
211	Wirksamkeit von topischem Koffein bei androgenetischer Alopezie des Mannes. JDDG - Journal of the German Society of Dermatology, 2017, 15, 734-741.	0.4	0
212	Therapeutische Patientenschulungsprogramme und UnterstÄ¼tzung beim Selbstmanagement fÄ¼r Patienten mit Psoriasis – eine systematische Åbersicht. JDDG - Journal of the German Society of Dermatology, 2019, 17, 685-697.	0.4	0
213	Behandlung ausgedehnter, therapieresistenter Keloide mit einer Kombination aus intralÄsionaler Kryochirurgie, Triamcinolon, 5Ä½Fluorouracil und Hyaluronidase. JDDG - Journal of the German Society of Dermatology, 2019, 17, 735-737.	0.4	0
214	Clindamycin alone may be enough. Is it time to abandon rifampicin for hidradenitis suppurativa? Reply from the authors. British Journal of Dermatology, 2019, 180, 1262-1263.	1.4	0
215	Confirming the Hypothesis at any Cost?. Deutsches Ärztblatt International, 2014, 111, 35.	0.6	0
216	Leitlinie zum Management IgE-vermittelter Nahrungsmittelallergien. Allergologie, 2016, 39, 302-344.	0.1	0

#	ARTICLE	IF	CITATIONS
217	Evidence Based Medicineâ€™s Perspective on Biologics. , 2007, , 184-186.		0
218	Narben und Keloide: Eine therapeutische Herausforderung. , 0, , .		0